BACKGROUND/AIM: Although some previous studies suggested that programmed cell death-ligand 1 (PD-L1) expression was significantly associated with a favorable postoperative prognosis in patients with small-cell lung cancer (SCLC), the prognostic significance of PD-L2 expression remains unknown. The aim of the current study was to investigate the prognostic significance of PD-L2 expression in patients with SCLC. PATIENTS AND METHODS: Thirty-eight patients who underwent resection of SCLC were analyzed. A monoclonal anti-human PD-L1 antibody (clone SP142) and a monoclonal anti-human PD-L2 antibody (clone 176611) were used as the primary antibodies. Cut-off value for PD-L1 and PD-L2 expression was set to 1%. RESULTS: Among 38 patients, 15 (39.5%) were positive for PD-L2 expression. No significant associations between PD-L2-positivity and clinicopathological factors, including PD-L1 positivity or prognosis were identified. No significant differences in disease-free survival and overall survival were observed between PD-L2-positive patients and PD-L2-negative patients (p=0.367 and p=0.726, respectively). CONCLUSION: PD-L2 expression is not related to clinicopathological factors or postoperative prognosis in patients with SCLC, though this should be further investigated in studies involving larger populations. Copyright
BACKGROUND/AIM: Although some previous studies suggested that programmed cell death-ligand 1 (PD-L1) expression was significantly associated with a favorable postoperative prognosis in patients with small-cell lung cancer (SCLC), the prognostic significance of PD-L2 expression remains unknown. The aim of the current study was to investigate the prognostic significance of PD-L2 expression in patients with SCLC. PATIENTS AND METHODS: Thirty-eight patients who underwent resection of SCLC were analyzed. A monoclonal anti-humanPD-L1 antibody (clone SP142) and a monoclonal anti-humanPD-L2 antibody (clone 176611) were used as the primary antibodies. Cut-off value for PD-L1 and PD-L2 expression was set to 1%. RESULTS: Among 38 patients, 15 (39.5%) were positive for PD-L2 expression. No significant associations between PD-L2-positivity and clinicopathological factors, including PD-L1 positivity or prognosis were identified. No significant differences in disease-free survival and overall survival were observed between PD-L2-positive patients and PD-L2-negative patients (p=0.367 and p=0.726, respectively). CONCLUSION:PD-L2 expression is not related to clinicopathological factors or postoperative prognosis in patients with SCLC, though this should be further investigated in studies involving larger populations. Copyright
Authors: Portia L Thomas; Sarah M Groves; Yun-Kai Zhang; Jia Li; Paula Gonzalez-Ericsson; Shamilene Sivagnanam; Courtney B Betts; Hua-Chang Chen; Qi Liu; Cindy Lowe; Heidi Chen; Kelli L Boyd; Prasad R Kopparapu; Yingjun Yan; Lisa M Coussens; Vito Quaranta; Darren R Tyson; Wade Iams; Christine M Lovly Journal: J Thorac Oncol Date: 2021-04-08 Impact factor: 20.121
Authors: Julius July; Diana Patricia; Pricilla Yani Gunawan; Handrianto Setiajaya; Teridah Ernala Ginting; Teguh Pribadi Putra; Zerlina Wuisan; Dini Budhiarko; Najmiatul Masykura; Gintang Prayogi; Ahmad Rusdan Utomo; Steven Tandean; Michael Lumintang Loe Journal: Pan Afr Med J Date: 2020-08-20
Authors: Anna Maria Di Giacomo; Monica Valente; Alfonso Cerase; Maria Fortunata Lofiego; Francesca Piazzini; Luana Calabrò; Elisabetta Gambale; Alessia Covre; Michele Maio Journal: J Exp Clin Cancer Res Date: 2019-10-17